U.S. markets open in 8 hours 47 minutes
  • S&P Futures

    3,759.00
    -6.50 (-0.17%)
     
  • Dow Futures

    30,830.00
    -48.00 (-0.16%)
     
  • Nasdaq Futures

    12,425.00
    -30.00 (-0.24%)
     
  • Russell 2000 Futures

    2,137.90
    -6.60 (-0.31%)
     
  • Crude Oil

    64.37
    +0.54 (+0.85%)
     
  • Gold

    1,691.70
    -9.00 (-0.53%)
     
  • Silver

    25.27
    -0.19 (-0.75%)
     
  • EUR/USD

    1.1963
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.5500
    -1.5500 (-100.00%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3890
    -0.0004 (-0.03%)
     
  • USD/JPY

    108.0700
    +0.0940 (+0.09%)
     
  • BTC-USD

    47,170.66
    -2,425.83 (-4.89%)
     
  • CMC Crypto 200

    942.15
    -45.06 (-4.56%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,653.85
    -276.26 (-0.95%)
     

Is Bio-Techne Corp (TECH) a Smart Long-term Buy?

  • Oops!
    Something went wrong.
    Please try again later.
Alex Smith
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Baron Asset Fund recently published its third-quarter commentary – a copy of which can be downloaded here. During the third quarter of 2020, the Baron Asset Fund returned 8.43% (institutional shares). In comparison, the benchmark S&P 500 Index was up 8.93%, while the Russell Midcap Growth Index was up 9.37%. You should check out Baron Asset Fund’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.

In the Q3 2020 Investor Letter, Baron Asset Fund highlighted a few stocks and Bio-Techne Corp (NASDAQ:TECH) is one of them. Bio-Techne Corp (NASDAQ:TECH) is a biotechnology company. Year-to-date, Bio-Techne Corp (NASDAQ:TECH) stock gained 40.3% and on December 7th it had a closing price of $307.93. Here is what Baron Asset Fund said:

"Bio-Techne Corporation detracted from performance in the quarter. Bio-Techne is a leading provider of life sciences tools to academic labs and biopharmaceutical customers. The company’s business is being negatively impacted by COVID-19 as academic lab customers are spending less time in their labs. We continue to believe Bio-Techne has a resilient business with over 80% of revenue from high-margin consumables in stable end markets (biopharmaceutical R&D, academic research, and diagnostics), where longterm growth is being driven by increased investment in life sciences."

Easiest Md/PhD Programs to Get Into
Easiest Md/PhD Programs to Get Into

Pressmaster/Shutterstock.com

In Q2 2020, the number of bullish hedge fund positions on Bio-Techne Corp (NASDAQ:TECH) stock increased by about 4% from the previous quarter (see the chart here), so a number of other hedge fund managers believe in Bio-Techne's growth potential. Our calculations showed that Bio-Techne Corp (NASDAQ:TECH) isn't ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 216% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 121 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds' poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.